Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada

BACKGROUND: Bipolar disorder (BPD) is prevalent and is associated with a significant economic burden. Asenapine, the first tetracyclic antipsychotic approved in Canada for the treatment of BPD, has shown a comparable efficacy profile to other atypical antipsychotics. In addition, it is associated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lachaine, Jean, Beauchemin, Catherine, Mathurin, Karine, Gilbert, Dominique, Beillat, Maud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905654/
https://www.ncbi.nlm.nih.gov/pubmed/24450548
http://dx.doi.org/10.1186/1471-244X-14-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905654/
https://www.ncbi.nlm.nih.gov/pubmed/24450548
http://dx.doi.org/10.1186/1471-244X-14-16

Ejemplares similares